Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials

@article{Lee2018ComparativeEA,
  title={Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials},
  author={Y H Lee and Gwan Gyu Song},
  journal={Lupus},
  year={2018},
  volume={27},
  pages={112 - 119}
}
Objective In this study, we aimed to assess the relative efficacy and safety of intravenous (IV) or subcutaneous (SC) belimumab compared with those of placebo in patients with active systemic lupus erythematosus (SLE). Methods We performed a Bayesian network meta-analysis to combine the direct and indirect evidence from randomized controlled trials (RCTs) examining the efficacy and safety of belimumab 1 mg/kg and 10 mg/kg IV administration, and belimumab 200 mg SC injection, and placebo in… 

Figures and Tables from this paper

An indirect comparison of intravenous and subcutaneous belimumab efficacy in patients with SLE and high disease activity.
TLDR
This indirect treatment comparison provides further evidence of the efficacy of belimumab IV and SC in patients with systemic lupus erythematosus and HDA, compared with standard therapy.
Belimumab for systemic lupus erythematosus.
TLDR
The belimumab 10 mg/kg group showed greater improvement in glucocorticoid dose, with a higher proportion of participants reducing their dose by at least 50% compared to placebo, and change in health-related quality of life (HRQOL), showed there was probably little or no difference between groups.
Belimumab: A Review in Systemic Lupus Erythematosus
TLDR
Treatment with IV or SC belimumab plus standard therapy was effective in terms of reducing overall disease activity and reducing the incidence and severity of flares, without worsening of patients’ overall condition or the development of significant disease activity in new organ systems.
Potential and prognostic factor for belimumab-free remission in patients with systemic lupus erythematosus: a single-center retrospective analysis
TLDR
Belimumab discontinuation can be considered for patients who achieved good responses, and normalization of complement, anti-dsDNA antibody, SELENA-SLEDAI less than 4, and steroid dosage less than 5 mg/day might be prognostic markers for belimumab-free remission.
Belimumab in systemic lupus erythematosus: a profile of its use
TLDR
In adults with active, autoantibody-positive SLE, add-on belimumab improves overall disease activity and flare rates and appears to have a steroid-sparing effect and disease control is maintained over long-term use.
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review
TLDR
Several novel biologic agents targeting B cells, T cells, or cytokines are constantly being evaluated in clinical trials and it seems that they may enhance the therapeutic efficacy when combined with standard therapies.
Subcutaneous belimumab in the treatment of systemic lupus erythematosus.
TLDR
This paper will review the major belimumab trials with a focus on the subcutaneous form and recommend several new drugs for the treatment of systemic lupus.
B Cell-Based Treatments in SLE: Past Experience and Current Directions
TLDR
Focusing specifically on autoreactive instead of non-specifically altering/depleting lupus, B cell depletion with rituximab is indeed employed worldwide, particularly in standard treatment refractory l upus, with promising results.
2020 Chinese guidelines for the diagnosis and treatment of systemic lupus erythematosus
TLDR
This guideline serves as an evidence-based tool for Chinese clinicians to diagnose and treat patients with SLE and provided recommendations for SLE classification criteria, disease activity monitoring and assessment, medication administration and considerations for Sle patients with organs and systems involved, and management of special populations such as SLE patients in the setting of pregnancy.
...
1
2
...

References

SHOWING 1-10 OF 39 REFERENCES
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
TLDR
Belimumab was biologically active and well tolerated and the effect of belimumab on the reduction of SLE disease activity or flares was not significant, however, serologically active SLE patients responded significantly better to belicumab therapy plus SOC than to SOC alone.
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
TLDR
Belimumab plus standard therapy significantly improved SRI response rate, reduced SLE disease activity and severe flares, and was generally well tolerated in SLE.
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
TLDR
In patients with SLE from North East Asia, belimumab significantly improved disease activity, while reducing prednisone use, with no new safety issues.
Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus
TLDR
The conclusion that belimumab in combination with standard SLE therapy was generally well tolerated in a predominantly autoantibody-positive population with active SLE is supported.
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
TLDR
It is suggested that belimumab has greater therapeutic benefit than standard therapy alone in patients with higher disease activity, anti-dsDNA positivity, low complement or corticosteroid treatment at baseline.
Novel evidence-based systemic lupus erythematosus responder index.
TLDR
This evidence-based evaluation of a large randomized, placebo-controlled trial in SLE resulted in the ability to define a robust responder index based on improvement in disease activity without worsening the overall condition or the development of significant disease activity in new organ systems.
Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis
TLDR
A systematic review and meta-analysis of randomised controlled trials of belimumab for patients with systemic lupus erythematosus and antinuclear and/or anti-double-stranded DNA (dsDNA) autoantibodies found results were systematically more favourable for all measured outcomes.
Current and emerging treatment options in the management of lupus
TLDR
The importance of managing comorbidities such as cardiovascular risk factors, bone health, and minimizing susceptibility to infection should not be neglected.
...
1
2
3
4
...